A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of SGN-35 and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Patients at High Risk of Residual Hodgkin Lymphoma Following Autologous Stem Cell Transplant

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Brentuximab vedotin (Primary)
  • Indications Hodgkin's disease
  • Focus Registrational; Therapeutic Use
  • Acronyms AETHERA
  • Sponsors Seattle Genetics; Takeda

    • Most Recent Events

    • 25 Jul 2017 According to a Seattle Genetics media release, based on data from this study, Health Canada has approved brentuximab vedotin for treatment of patients with Hodgkin lymphoma (HL) at increased risk of relapse or progression.
    • 09 Jun 2017 This trial has been completed in Germany.
    • 27 Oct 2016 According to Seattle Genetics media release, data was presented at the 10th International Symposium on Hodgkin Lymphoma (ISHL) in October 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top